NO973366D0 - Fremgangsmåte for behandling av multippel sklerose - Google Patents
Fremgangsmåte for behandling av multippel skleroseInfo
- Publication number
- NO973366D0 NO973366D0 NO973366A NO973366A NO973366D0 NO 973366 D0 NO973366 D0 NO 973366D0 NO 973366 A NO973366 A NO 973366A NO 973366 A NO973366 A NO 973366A NO 973366 D0 NO973366 D0 NO 973366D0
- Authority
- NO
- Norway
- Prior art keywords
- procedure
- treatment
- multiple sclerosis
- sclerosis
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preliminary Treatment Of Fibers (AREA)
- Quinoline Compounds (AREA)
- Treatment Of Fiber Materials (AREA)
- Spinning Or Twisting Of Yarns (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37660695A | 1995-01-23 | 1995-01-23 | |
| PCT/US1996/000856 WO1996022772A1 (en) | 1995-01-23 | 1996-01-22 | Method for treating multiple sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO973366L NO973366L (no) | 1997-07-21 |
| NO973366D0 true NO973366D0 (no) | 1997-07-21 |
Family
ID=23485697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO973366A NO973366D0 (no) | 1995-01-23 | 1997-07-21 | Fremgangsmåte for behandling av multippel sklerose |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5731336A (no) |
| EP (1) | EP0722729A3 (no) |
| JP (1) | JPH10512883A (no) |
| KR (1) | KR19980701588A (no) |
| AU (1) | AU690814B2 (no) |
| CA (1) | CA2210566A1 (no) |
| CZ (1) | CZ233897A3 (no) |
| HU (1) | HUP9702293A3 (no) |
| MX (1) | MX9705557A (no) |
| NO (1) | NO973366D0 (no) |
| WO (1) | WO1996022772A1 (no) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0914122B1 (en) * | 1996-07-11 | 2003-09-24 | Warner-Lambert Company LLC | Method for treating and preventing neurodegenerative disorders by administering a thiazolidinone |
| US6218437B1 (en) * | 1996-09-30 | 2001-04-17 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
| AU2003245555A1 (en) | 2002-06-17 | 2003-12-31 | The Pennsylvania State Research Foundation | Sphingosine kinase inhibitors |
| AU2002953533A0 (en) | 2002-12-24 | 2003-01-16 | Arthron Limited | Fc receptor modulating compounds and compositions |
| EP2278879B1 (en) | 2008-04-21 | 2016-06-15 | PATH Drug Solutions | Compounds, compositions and methods comprising oxadiazole derivatives |
| WO2009131951A2 (en) | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
| US8343976B2 (en) | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
| US8933075B2 (en) * | 2010-06-17 | 2015-01-13 | Fuzians Biomedicals, Inc. | Compounds useful as antiviral agents, compositions, and methods of use |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4791126A (en) * | 1980-08-22 | 1988-12-13 | Ono Pharmaceutical Co., Ltd. | Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredients |
| JPS5740478A (en) * | 1980-08-22 | 1982-03-06 | Ono Pharmaceut Co Ltd | Rhodanine derivative, its preparation and aldose reductase inhibitor containing rhodanine derivative |
| JPS5785380A (en) * | 1980-11-18 | 1982-05-28 | Hisamitsu Pharmaceut Co Inc | Thiazolidone derivative |
| PT83152B (pt) * | 1985-08-09 | 1989-03-30 | Lilly Co Eli | Processo para a preparacao de compostos di-t-butilfenoicos |
| US5356917A (en) * | 1985-08-09 | 1994-10-18 | Eli Lilly And Company | Aryl-substituted rhodanine derivatives |
| WO1988007035A1 (en) * | 1987-03-11 | 1988-09-22 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Hydroxystyrene derivatives |
| US4897406A (en) * | 1987-11-13 | 1990-01-30 | Nisshin Flour Milling Co., Ltd. | Rhodanine derivatives and pharmaceutical compositions |
| IE62214B1 (en) * | 1988-05-25 | 1995-01-11 | Warner Lambert Co | Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents |
| NZ231534A (en) * | 1988-11-29 | 1992-02-25 | Warner Lambert Co | 3,5-di-t-butyl-4-hydroxyphenyl-triazoles, oxadiazoles and thiadiazoles; anti-inflammatory compositions |
| ZA902520B (en) * | 1989-04-07 | 1991-12-24 | Lilly Co Eli | Aryl-substituted rhodanine derivatives |
| JPH02300119A (ja) * | 1989-05-11 | 1990-12-12 | Kanegafuchi Chem Ind Co Ltd | 過酸化脂質生成抑制剤 |
| EP0398179B1 (en) * | 1989-05-19 | 1996-01-17 | Nisshin Flour Milling Co., Ltd. | Rhodanine derivatives and pharmaceutical compositions |
| US5216002A (en) * | 1989-12-21 | 1993-06-01 | Eli Lilly And Company | Method of treating inflammatory bowel disease |
| HU214872B (hu) * | 1990-04-27 | 1998-07-28 | Orion-Yhtymä Oy | Eljárás farmakológiailag aktív új katecholszármazékok és ezeket tartalmazó gyógyászati készítmények előállítására |
| DE4027038A1 (de) * | 1990-08-27 | 1992-03-05 | Wella Ag | 3-amino-5-benzyliden-2-thioxo-thiazolidin-4- one, verfahren zu deren herstellung und diese enthaltendes kosmetisches mittel |
| US5158966A (en) * | 1991-02-22 | 1992-10-27 | The University Of Colorado Foundation, Inc. | Method of treating type i diabetes |
-
1996
- 1996-01-22 EP EP96300415A patent/EP0722729A3/en not_active Withdrawn
- 1996-01-22 JP JP8522965A patent/JPH10512883A/ja active Pending
- 1996-01-22 MX MX9705557A patent/MX9705557A/es unknown
- 1996-01-22 WO PCT/US1996/000856 patent/WO1996022772A1/en not_active Application Discontinuation
- 1996-01-22 CZ CZ972338A patent/CZ233897A3/cs unknown
- 1996-01-22 AU AU47038/96A patent/AU690814B2/en not_active Ceased
- 1996-01-22 CA CA002210566A patent/CA2210566A1/en not_active Abandoned
- 1996-01-22 KR KR1019970704980A patent/KR19980701588A/ko not_active Application Discontinuation
- 1996-01-22 HU HU9702293A patent/HUP9702293A3/hu unknown
- 1996-02-20 US US08/603,358 patent/US5731336A/en not_active Expired - Fee Related
-
1997
- 1997-07-21 NO NO973366A patent/NO973366D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996022772A1 (en) | 1996-08-01 |
| HUP9702293A3 (en) | 2000-08-28 |
| CA2210566A1 (en) | 1996-08-01 |
| AU4703896A (en) | 1996-08-14 |
| MX9705557A (es) | 1997-10-31 |
| EP0722729A3 (en) | 1997-11-26 |
| JPH10512883A (ja) | 1998-12-08 |
| HUP9702293A2 (hu) | 1998-04-28 |
| EP0722729A2 (en) | 1996-07-24 |
| CZ233897A3 (cs) | 1998-03-18 |
| NO973366L (no) | 1997-07-21 |
| AU690814B2 (en) | 1998-04-30 |
| KR19980701588A (ko) | 1998-05-15 |
| US5731336A (en) | 1998-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO976063D0 (no) | Fremgangsmåte for behandling av diabetes | |
| FI964874A (fi) | Vihannesten käsittely | |
| NO961483D0 (no) | Fremgangsmåte for behandling av oljeholdig formasjon | |
| NO991955L (no) | FremgangsmÕte for behandling av hydrokarboner | |
| NO982172D0 (no) | Anvendelse av epinastin for behandling av smerter | |
| NO965377L (no) | Indolinonforbindelser for behandling av sykdommer | |
| NO961006L (no) | Fosfonomononukleinsyrer, fremgangsmåter for fremstilling derav og anvendelse av forbindelsene | |
| NO986054D0 (no) | Antikonvulsive derivater for behandling av amyotrofisk lateral sklerose (AL | |
| NO990225D0 (no) | Medikamenter for behandling av hyperfosfatemi | |
| NO963785D0 (no) | Fremgangsmåte for behandling av 5HT2B-reseptor-relaterte betingelser | |
| FI962370A0 (fi) | Laite tissuen valmistamiseksi | |
| NO944871L (no) | Fremgangsmåte for fremstilling av polydimetylsiloksaner | |
| NO982911D0 (no) | FremgangsmÕte for behandling av depresjon | |
| AU7310896A (en) | Use of nitroflavonoids for the treatment of anxiety | |
| NO930574L (no) | Fremgangsmaate for fremstilling av desfluran | |
| NO932850L (no) | Fremgangsmaate for fremstilling av staal | |
| NO973366D0 (no) | Fremgangsmåte for behandling av multippel sklerose | |
| NO982582D0 (no) | FremgangsmÕte for behandling av smerte | |
| EE9700235A (et) | Benseenamiidid neurodegeneratiivsete haiguste ravimiseks | |
| FI980091A0 (fi) | Menetelmä ylijäämäaktiivilietteen käsittelemiseksi | |
| NO982562D0 (no) | Sammensetning for behandling av smerte | |
| NO991158D0 (no) | FremgangsmÕte for behandling av amyotrofisk lateralsklerose | |
| NO963432D0 (no) | Fremgangsmåte for fremstilling av dimetyldiklorsilan | |
| FI942576A0 (fi) | Behandling av plasma | |
| NO974747D0 (no) | Fremgangsmåte for fremstilling av streptograminer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |